Efficiency of CMV serodiagnosis during pregnancy in daily laboratory routine

Müller, Jens; Flindt, Juliane; Pollmann, M.; Saschenbrecker, Sandra; Borchardt, Viola; Warnecke, Jens M.

doi:10.1016/j.jviromet.2023.114685

Cited by 5 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Identification of antibodies against CMV-specific antigens has also been evaluated clinically because of their ability to differentiate between primary and established HCMV infections. Muller and colleagues 64 reported on the use of anti-p52 IgM and anti-gB IgG compared to routine IgG, IgM, and avidity assays during pregnancy to return “conclusive results” (i.e., susceptible to infection, acute primary infection, recurrent infection/reactivation, or past infection). These investigators found the use of anti-p52 IgM and anti-gB IgG produced conclusive results in 513/553 [92.8%, 95% confidence interval (CI): 90.3-94.7%] compared to routine IgG, IgM, and avidity testing 468/553 (84.6%, 95% CI: 81.4%-87.4%).…”

Section: Prenatal Detectionmentioning

confidence: 99%

Decoding human cytomegalovirus for the development of innovative diagnostics to detect congenital infection

Lawrence,

Goshia,

Sinha

et al. 2023

Pediatr Res

View full text Add to dashboard Cite

Cytomegalovirus is the most common cause of congenital infectious disease and the leading nongenetic etiology of sensorineural hearing loss. Although most infected neonates are asymptomatic at birth, congenital cytomegalovirus infection is responsible for nearly 400 infant deaths annually in the United States and may lead to significant long-term neurodevelopmental impairments in survivors. The resulting financial and social burdens of congenital cytomegalovirus infection have led many medical centers to initiate targeted testing after birth, with a growing advocacy to advance universal newborn screening. While no cures or vaccines are currently available to eliminate or prevent cytomegalovirus infection, much has been learned over the last five years regarding disease pathophysiology and viral replication cycles that may enable the development of innovative diagnostics and therapeutics. This Review will detail our current understanding of congenital cytomegalovirus infection, while focusing our discussion on routine and emerging diagnostics for viral detection, quantification, and long-term prognostication. Impact This review highlights our current understanding of the fetal transmission of human cytomegalovirus. It details clinical signs and physical findings of congenital cytomegalovirus infection. This submission discusses currently available cytomegalovirus diagnostics and introduces emerging platforms that promise improved sensitivity, specificity, limit of detection, viral quantification, detection of genomic antiviral resistance, and infection staging (primary, latency, reactivation, reinfection).

show abstract

Section: Prenatal Detectionmentioning

confidence: 99%

Decoding human cytomegalovirus for the development of innovative diagnostics to detect congenital infection

Lawrence,

Goshia,

Sinha

et al. 2023

Pediatr Res

View full text Add to dashboard Cite

show abstract

“…Serological testing is often the reference diagnostic method for risk assessment in the prenatal/preconception field. The conventional approach of assessing the mother's immune status using HCMV-specific antibodies entails the detection of anti-HCMV IgG and IgM antibodies as well as, in the case of IgG positivity, the measurement of IgG avidity [47]. Furthermore, the assessment of donor and recipient HCMV serologic status prior to transplantations is currently used as a marker for latent infection and the subsequent risk for donor-derived transmission and immune competence.…”

Section: Introductionmentioning

confidence: 99%

Antiviral Approach to Cytomegalovirus Infection: An Overview of Conventional and Novel Strategies

Bottino,

Pastrone,

Curtoni

et al. 2023

Microorganisms

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) is a herpesvirus capable of establishing a lifelong persistence in the host through a chronic state of infection and remains an essential global concern due to its distinct life cycle, mutations, and latency. It represents a life-threatening pathogen for immunocompromised patients, such as solid organ transplanted patients, HIV-positive individuals, and hematopoietic stem cell recipients. Multiple antiviral approaches are currently available and administered in order to prevent or manage viral infections in the early stages. However, limitations due to side effects and the onset of antidrug resistance are a hurdle to their efficacy, especially for long-term therapies. Novel antiviral molecules, together with innovative approaches (e.g., genetic editing and RNA interference) are currently in study, with promising results performed in vitro and in vivo. Since HCMV is a virus able to establish latent infection, with a consequential risk of reactivation, infection management could benefit from preventive treatment for critical patients, such as immunocompromised individuals and seronegative pregnant women. This review will provide an overview of conventional antiviral clinical approaches and their mechanisms of action. Additionally, an overview of proposed and developing new molecules is provided, including nucleic-acid-based therapies and immune-mediated approaches.

show abstract